Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis

Figures & data

Figure 1 Flow diagram of the meta-analysis study selection process.

Abbreviations: SBRT, stereotactic body radiotherapy; SABR, stereotactic ablative radiotherapy; RCT, randomized controlled trial.

Table 1 Basic characteristics of all of the pooled studies in the meta-analysis

Study	Year	Country	Studydesign	TNM (7th edition)	Number of patients		Age (mean ± SD or range)		Gender (male/female)
					SBRT/SABR	Surgery	SBRT/SABR	Surgery	SBRT/SABR	Surgery
Wang et al^Citation12	2016	People’s Republic of China	RS	T1N0M0	35	35	77.1±5.2	74.8±6.6	33/2	33/2
Rosen et al^Citation11	2016	USA	RS	T1/2aN0M0	1,781	1,781	75.5±9.1	74.8±7.8	1,014/767	1,004/777
Ezer et al^Citation13	2015	Canada and USA	RS	T1/2aN0M0	362	1,881	78±6.5	76±5.7	127/235	809/1,072
Hamaji et al^Citation14	2015	Japan	RS	T1/2aN0M0	41	41	73 (58–85)	74 (61–86)	31/10	32/9
van den Berg et al^Citation15	2015	the Netherlands	RS	T1/2aN0M0	197	143	77 (52–93)	67 (40–84)	143/54	96/47
Chang et al^Citation16	2015	USA	RCT	T1/2aN0M0	31	27	67.1 (43–82)	66.7 (51–85)	14/17	11/16
Kastelijn et al^Citation17	2015	the Netherlands	RS	T1/2N0M0	53	175	71.6±10.2	66.5±9.1	19/34	109/66
Nakagawa et al^Citation18	2014	Japan	RS	T1/2aN0M0	35	183	79.8±2.8	78.3±2.5	25/10	122/61
Matsuo et al^Citation19	2014	Japan	RS	T1/2aN0M0	53	53	76 (58–86)	76 (50–88)	42/11	37/16
Port et al^Citation20	2014	USA	RS	T1N0M0	23	76	76 (70–79)	72 (66–77)	12/11	26/50
Crabtree et al^Citation5	2014	USA	RS	T1/2aN0M0	56	56	70.0±8.1	70.7±10.6	29/27	32/24
Verstegen et al^Citation6	2013	the Netherlands	RS	T1-3N0M0	64	64	67.95±8.84	70.53±9.91	37/27	36/28
Varlotto et al^Citation21	2013	USA	RS	T1/2N0M0	137	180	73.3 (51–92)	68.3 (38–87)	66/71	99/81
Palma et al^Citation7	2011	the Netherlands	RS	T1/2N0M0	60	60	79 (76–81)	79 (76–80)	40/20	40/20
Grills et al^Citation22	2010	USA	RS	T1/2N0M0	58	69	74 (69–78)	78 (55–89)	22/36	28/41

Abbreviations: SD, standard deviation; SBRT, stereotactic body radiotherapy; SABR, stereotactic ablative radiotherapy; RS, retrospective study; RCT, randomized controlled trial; TNM, TNM classification of malignant tumors.

Figure 2 Forest plot of the survival for SBRT/SABR group versus surgical group. Including the OS (A) and the RFS (B).

Abbreviations: IV, inverse variance; CI, confidence interval; SBRT, stereotactic body radiotherapy; SABR, stereotactic ablative radiotherapy; OS, overall survival; RFS, recurrence-free survival.

Figure 3 Results publication bias analysis – funnel plot.

Figure 4 Forest plot of the incidence of recurrence for SBRT/SABR group versus surgical group, including (A) the incidence of locoregional recurrence and (B) the incidence of distant recurrence.

Abbreviations: IV, inverse variance; CI, confidence interval; SBRT, stereotactic body radiotherapy; SABR, stereotactic ablative radiotherapy.

Figure 5 Forest plot of the OS for SBRT/SABR group versus different surgical groups, including (A) the OS for SBRT/SABR group versus lobectomy, (B) the OS for SBRT/SABR group versus sublobectomy, and (C) the OS for SBRT/SABR group versus wedge resection.

Abbreviations: IV, inverse variance; CI, confidence interval; SBRT, stereotactic body radiotherapy; SABR, stereotactic ablative radiotherapy; OS, overall survival.

WangPZhangDGuoXGA propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderlyMedicine (Baltimore)20169552e572328033277

 PubMedGoogle Scholar

RosenJESalazarMCWangZLobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancerJ Thorac Cardiovasc Surg201615214454.e927131846

 PubMed Web of Science ®Google Scholar

EzerNVeluswamyRRMhangoGRosenzweigKEPowellCAWisniveskyJPOutcomes after stereotactic body radiotherapy versus limited resection in older patients with early-stage lung cancerJ Thorac Oncol20151081201120626200275

 PubMed Web of Science ®Google Scholar

HamajiMChenFMatsuoYVideo-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancerAnn Thorac Surg20159941122112925661580

 PubMed Web of Science ®Google Scholar

van den BergLLKlinkenbergTJGroenHJWidderJPatterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLCJ Thorac Oncol201510582683125629639

 PubMedGoogle Scholar

ChangJYSenanSPaulMAStereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsLancet Oncol201516663063725981812

 PubMed Web of Science ®Google Scholar

KastelijnEAEl SharouniSYHofmanFNClinical outcomes in early-stage NSCLC treated with stereotactic body radiotherapy versus surgical resectionAnticancer Res201535105607561426408733

 PubMed Web of Science ®Google Scholar

NakagawaTNegoroYMatsuokaTOkumuraNDodoYComparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancerRespir Investig2014524221226

 PubMedGoogle Scholar

MatsuoYChenFHamajiMComparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysisEur J Cancer201450172932293825281527

 PubMed Web of Science ®Google Scholar

PortJLParasharBOsakweNA propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancerAnn Thorac Surg20149841152115925085557

 PubMed Web of Science ®Google Scholar

CrabtreeTDPuriVRobinsonCAnalysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapyJ Thorac Cardiovasc Surg2014147411831191 discussion 1191–119224507980

 PubMed Web of Science ®Google Scholar

VerstegenNEOosterhuisJWPalmaDAStage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysisAnn Oncol20132461543154823425947

 PubMed Web of Science ®Google Scholar

VarlottoJFakirisAFlickingerJMatched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgeryCancer2013119152683269123605504

 PubMed Web of Science ®Google Scholar

PalmaDVisserOLagerwaardFJBelderbosJSlotmanBSenanSTreatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgeryRadiother Oncol2011101224024421775007

 PubMedGoogle Scholar

GrillsISMangonaVSWelshROutcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancerJ Clin Oncol201028692893520065181

 PubMed Web of Science ®Google Scholar